Major Cancer definition

Major Cancer means a malignant tumour characterised by the uncontrolled growth and spread of malignant cells with invasion and destruction of normal tissue. This Diagnosis must be supported by histological evidence of malignancy and confirmed by an oncologist or pathologist.
Sample 1Sample 2Sample 3
Major Cancer means the occurrence of (i) or (ii): (i) Any malignant tumour positively Unequivocally Diagnosed with histological confirmation and characterized by the uncontrolled growth of malignant cells and invasion of tissue; or(ii) Any occurrence of histologically confirmed leukemia, lymphoma or sarcoma. Irrespective of the above, Major Cancer does not include carcinoma-in-situ.“Public Health Emergency of International Concern”shall mean a formal declaration by the World Health Organization of an extraordinary event which is determined to constitute a public health risk to other states through the international spread of disease and to potentially require a coordinated international response, which is still valid and not expired on the date of Unequivocal Diagnosis.“Respiratory Diseases”shall mean an Unequivocal Diagnosis of any one (1) of the following conditions:(i) End Stage Lung Disease(ii) Single or Double-Lung Transplant(iii) Severe Asthma(iv) Severe Bronchiectasis(v) Severe Chronic Obstructive Lung Disease(vi) Severe Emphysema(vii) Severe Pulmonary Fibrosis(viii) Single-Lung Surgery The Unequivocal Diagnosis must be confirmed by a Specialist in the relevant medical field.“Severe Asthma”shall mean the Insured Person suffering from severe asthma which is characterized by at least three (3) of the following:(i) history of status asthmaticus within the past two (2) years;(ii) significant and continuous reduction in exercise tolerance, as certified by a Registered Medical Practitioner;(iii) chest deformities resulting from chronic hyperinflation;(iv) the need for regular oxygen therapy at home as prescribed by a Registered Medical Practitioner; and(v) continuous daily use of oral corticosteroids (for a minimum period of six (6) consecutive months) as prescribed by a Registered Medical Practitioner.“Severe Bronchiectasis”shall mean an Unequivocal Diagnosis of severe bronchiectasis requiring Extensive and Permanent Oxygen Therapy as well as FEV 1 test result of consistently less than one (1) litre as certified by a Specialist in the relevant medical field. “Severe Chronic Obstructive Lung Disease” shall mean an Unequivocal Diagnosis of severe chronic obstructive lung disease requiring Extensive and Permanent Oxygen Therapy as well as FEV 1 test result of consistently less than one (1) litre as certified by a Specialist in the relevant medical field. “Severe Emphysema” shall mean an Unequivocal Diagnosis of severe emphysema requiring Extensive and Permanent Oxygen T...
Sample 1Sample 2Sample 3
Major Cancer means the occurrence of (i) or (ii):
Sample 1

Examples of Major Cancer in a sentence

  • Major Cancer diagnosed on the basis of finding tumour cells and/or tumour-associated molecules in blood, saliva, faeces, urine or any other bodily fluid in the absence of further definitive and clinically verifiable evidence does not meet the above definition.

  • The term Major Cancer includes, but is not limited to, leukemia, lymphoma and sarcoma.

  • No Benefit shall be payable under this Master Policy in respect of any Major Cancer, Carcinoma-in-situ or Early Stage Cancer resulting directly or indirectly from or caused or contributed by (in whole or in part): 1.

  • Cancer PRSweb: An Online Repository with Polygenic Risk Scores for Major Cancer Traits and Their Evaluation in Two Independent Biobanks.

  • The term Major Cancer includes, but is not limited to, leukaemia, lymphoma and sarcoma.

  • For the avoidance of doubt, the Eligible Expenses for the Prescribed Diagnostic Imaging Tests conducted in relation to non-surgical cancer treatments shall be payable under Section 3(i) of Part 6 of the Terms and Benefits and shall not be payable under this Major Cancer top up benefit.

  • Critical illness means any one of the following: 1 Major Cancer A malignant tumour positively diagnosed with histological confirmation and characterised by the uncontrolled growth of malignant cells with invasion and destruction of normal tissue.

  • ExclusionsWe will not pay any Benefit under this Policy in respect of any Major Cancer, Carcinoma-in-situ or Early Stage Cancer resulting directly or indirectly from or caused or contributed by (in whole or in part): (a) Sexually Transmitted Diseases AIDS or HIV.

  • Any cancer diagnosed prior to the Policy Effective Date in the same body or organ site as the Major Cancer or any cancer which subsequently metastasised into the Major Cancer.

  • On diagnosis of Early Stage Cancer or CIS or Major Cancer during the Cover Term, subject to applicable exclusions, the following Benefits will be payable to the Scheme Member: A lump sum Benefit, as per the table below: Diagnosis of% of Applicable Cancer Cover Sum InsuredEarly Stage Cancer or CIS25% of Cancer Cover Sum InsuredMajor Cancer100% of Cancer Cover Sum Insuredless Early Stage Cancer orCIS claims, if any iii.


More Definitions of Major Cancer

Major Cancer means a malignant tumour positively diagnosed with histological confirmation and characterised by the uncontrolled growth of malignant cells with invasion and destruction of normal tissue.The term Major Cancer includes, but is not limited to, leukemia, lymphoma and sarcoma.Major Cancer diagnosed on the basis of finding tumour cells and/or tumour-associated molecules in blood, saliva, faeces, urine or any other bodily fluid in the absence of further definitive and clinically verifiable evidence does not meet the above definition.The following shall not fall within the definition of “Major Cancer” and are not covered under this Policy:
Sample 1

Related to Major Cancer

  • Stage-Four Advanced, Metastatic Cancer means a cancer that has spread from the primary or original site of the cancer to nearby tissues, lymph nodes, or other areas or parts of the body.

  • Pivotal Clinical Trial means a pivotal human clinical trial of a Licensed Product with a defined dose or a set of defined doses of such Licensed Product designed to ascertain efficacy and safety of such Licensed Product for the purpose of enabling the preparation and submission of an MAA to the competent Regulatory Authorities in a country of the Territory, as further defined in 21 C.F.R. § 312.21(c) for the U.S., as amended from time to time, or the corresponding foreign regulations.

  • Clinical Trial means a Phase I Clinical Trial, Phase II Clinical Trial or Phase III Clinical Trial, or any post-approval human clinical trial, as applicable.

  • Phase II Clinical Trial means a controlled human clinical study that would satisfy the requirements of 21 CFR 312.21(b), conducted to study the effectiveness and establish the dose range of a Product for a particular Indication in patients with the disease or condition under study, including a Phase IIA Clinical Study or Phase IIB Clinical Study.

  • sickle cell disease means a hemolytic disorder characterized by chronic anemia, painful events, and various complications due to associated tissue and organ damage; "hemolytic" refers to the destruction of the cell membrane of red blood cells resulting in the release of hemoglobin.

  • Phase 2 Clinical Trial means a human clinical trial of a product in any country that would satisfy the requirements of 21 C.F.R. 312.21(b) and is intended to explore a variety of doses, dose response, and duration of effect, and to generate initial evidence of clinical safety and activity in a target patient population, or a similar clinical study prescribed by the relevant Regulatory Authorities in a country other than the United States.

  • Phase 3 Clinical Trial means a pivotal clinical trial in humans performed to gain evidence with statistical significance of the efficacy of a product in a target population, and to obtain expanded evidence of safety for such product that is needed to evaluate the overall benefit-risk relationship of such product, to form the basis for approval of an NDA and to provide an adequate basis for physician labeling, as described in 21 C.F.R. § 312.21(c) or the corresponding regulation in jurisdictions other than the United States.

  • Phase IIb Clinical Trial means a clinical trial of a Product on sufficient numbers of patients that is designed to provide a preliminary determination of safety and efficacy of such Product in the target patient population over a range of doses and dose regimens.

  • Phase 3 Trial means a human clinical trial of a Product on a sufficient number of subjects that is designed to establish that a pharmaceutical product is safe and efficacious for its intended use, and to determine warnings, precautions and adverse reactions that are associated with such pharmaceutical product in the dosage range to be prescribed, which trial is intended to support Approval of a Product, as described in 21 C.F.R. 312.21(c) for the United States, or a similar clinical study prescribed by the Regulatory Authorities in a foreign country.

  • Development Candidate means a Compound that meets the Development Candidate Criteria for the initiation of a Development Program for the treatment of CF, and which is the subject of a notice from Vertex to CFFT that Vertex intends to commence formal pre-clinical development of the Compound in the Field pursuant to the provisions of Section 3.1 hereof.

  • Phase III Clinical Trial means a large, controlled or uncontrolled Clinical Study that would satisfy the requirements of 21 CFR 312.21(c), intended to gather the additional information about effectiveness and safety that is needed to evaluate the overall benefit-risk relationship of the drug and to provide an adequate basis for physician labeling.

  • Product Candidate means each of MYO-101, MYO-102, MYO-103, MYO-201 and MYO-301, as defined on Exhibit B, in each case in any form or formulation.

  • Phase 1 Clinical Trial means a Clinical Trial of a Product on sufficient numbers of normal volunteers and/or patients that is designed to establish that such Product is safe for its intended use and to support its continued testing in Phase 2 Clinical Trials. For purposes of this Agreement, ‘initiation’ of a Phase 1 Clinical Trial for a Product means the first dosing of such Product in a human subject in a Phase 1 Clinical Trial.

  • Phase 3 Study means a clinical study of an investigational product in patients that incorporates accepted endpoints for confirmation of statistical significance of efficacy and safety with the aim to obtain Regulatory Approval in any country as described in 21 C.F.R. 312.21(c), or a comparable Clinical Study prescribed by the relevant Regulatory Authority in a country other than the United States. The investigational product can be administered to patients as a single agent or in combination with other investigational or marketed agents [***]

  • Phase III Clinical Trials means a Clinical Trial for the Product on sufficient numbers of patients to generate safety and efficacy data to support Regulatory Approval in the proposed therapeutic indication, conducted in accordance with current good clinical practices and in accordance with a protocol that has been reviewed by the FDA and reflects any comments or concerns raised by the same.

  • Phase I Clinical Trial means a study in humans which provides for the first introduction into humans of a product, conducted in normal volunteers or patients to generate information on product safety, tolerability, pharmacological activity or pharmacokinetics, or otherwise consistent with the requirements of U.S. 21 C.F.R. §312.21(a) or its foreign equivalents.

  • Study means the investigation to be conducted in accordance with the Protocol.

  • Collaboration Compound means any of the following: (a) FG-4592, (b) any HIF Compound (other than FG-4592) that is added to this Agreement pursuant to Section 3.6, and (c) any salts, esters, complexes, chelates, crystalline and amorphous morphic forms, pegylated forms, enantiomers (excluding regioisomers), prodrugs, solvates, metabolites and catabolites of any of the foregoing ((a) or (b)).

  • Phase IV Clinical Trial means a product support clinical trial of a Product commenced after receipt of Regulatory Approval in the country where such trial is conducted. A Phase IV Clinical Trial may include epidemiological studies, modeling and pharmacoeconomic studies, and investigator-sponsored clinical trials studying Product that are approved by BMS and that otherwise fit the foregoing definition.

  • Medical cannabis means the same as that term is defined in Section 26-61a-102.

  • Pivotal Trial means a clinical study in humans of the efficacy and safety of a Licensed Product that is prospectively designed to demonstrate with statistical significance that such product is effective and safe for use in a particular indication in a manner sufficient to file for Marketing Approval of such product and would satisfy the requirements of 21 CFR 312.21(c), or a similar clinical study prescribed by the Regulatory Authorities in a country other than the United States.

  • Clinical Trials means a controlled study in humans of the safety or efficacy of a Product, and includes, without limitation, such clinical trials as are designed to support expanded labeling or to satisfy the requirements of an Agency in connection with any Product Approval and any other human study used in research and Development of a Product.

  • Treatability study means a study in which a hazardous waste is subjected to a treatment process to determine: (1) Whether the waste is amenable to the treatment process, (2) what pretreatment (if any) is required, (3) the optimal process conditions needed to achieve the desired treatment, (4) the efficiency of a treatment process for a specific waste or wastes, or (5) the characteristics and volumes of residuals from a particular treatment process. Also included in this definition for the purpose of the § 261.4 (e) and (f) exemptions are liner compatibility, corrosion, and other material compatibility studies and toxicological and health effects studies. A “treatability study” is not a means to commercially treat or dispose of hazardous waste.

  • Phase II Clinical Study means a human clinical study of a product initiated to determine the safety and efficacy in the target patient population, as described 21 C.F.R. 312.21(b).

  • Phase 4 Clinical Trial means a Clinical Study in any country which is conducted after Regulatory Approval of a product has been obtained from an appropriate Regulatory Authority, consisting of trials conducted voluntarily for enhancing marketing or scientific knowledge of an approved indication and trials conducted due to request or requirement of a Regulatory Authority.

  • Phase III Study means a human clinical trial that is prospectively designed to demonstrate statistically whether a product is safe and effective for use in humans in a manner sufficient to obtain regulatory approval to market such product in patients having the disease or condition being studied as described in 21 C.F.R. § 312.21(c) (FDCA), as amended from time to time, and the foreign equivalent thereof.